Hereditary cancer predisposition syndromes.

Cancer genetics is increasingly becoming integrated into the practice of modern medical oncology. The ability to distinguish a growing proportion of the 5% to 10% of all cancers that develop in individuals who have inherited a genetic mutation conferring heightened susceptibility to specific cancers may permit targeted efforts in cancer surveillance and prevention. While these individuals comprise a small proportion of the overall burden of cancer, strategies successful in reducing their remarkable cancer risks may be generalizable to the broader population. In this review, we highlight the most common hereditary cancer syndromes, most attributable to genes inherited in an autosomal dominant manner with incomplete penetrance, and a number of rare syndromes in which particular progress has been made. The prevalence, penetrance, tumor spectrum, and underlying genetic defects are discussed and summarized in a large table in which a more comprehensive enumeration of syndromes is provided.

[1]  W. Kaelin,et al.  von Hippel-Lindau disease. , 1997, Medicine.

[2]  W. Foulkes,et al.  Familial Adenomatous Polyposis , 2006, The American Journal of Gastroenterology.

[3]  K. Offit MSH6 mutations in hereditary nonpolyposis colon cancer: another slice of the pie. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Dallapiccola,et al.  Spectrum of PTCH mutations in Italian nevoid basal cell‐carcinoma syndrome patients: Identification of thirteen novel alleles , 2004, Human mutation.

[5]  K. Offit,et al.  Breast MRI for women with hereditary cancer risk. , 2004, JAMA.

[6]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[7]  W. Foulkes,et al.  BRCA1 and BRCA2: 1994 and beyond , 2004, Nature Reviews Cancer.

[8]  C. Eng,et al.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.

[9]  B. Gallie,et al.  Retinoblastoma: Revisiting the model prototype of inherited cancer , 2004, American journal of medical genetics. Part C, Seminars in medical genetics.

[10]  M. Leppert,et al.  Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. , 2004, Gastroenterology.

[11]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[12]  W. Foulkes,et al.  Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria , 2004, Journal of Medical Genetics.

[13]  E. Jordanova,et al.  Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families , 2004, Oncogene.

[14]  S. Leachman,et al.  Clinical germline genetic testing for melanoma. , 2004, The Lancet. Oncology.

[15]  K. Offit,et al.  BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews , 2004, Clinical Cancer Research.

[16]  Jakub Tolar,et al.  Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. , 2004, Blood.

[17]  Alison P. Klein,et al.  Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds , 2004, Cancer Research.

[18]  J. Klijn,et al.  Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.

[19]  D. Easton,et al.  Lifetime risks of common cancers among retinoblastoma survivors. , 2004, Journal of the National Cancer Institute.

[20]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[21]  P. Guilford,et al.  Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone , 2003, Gut.

[22]  L. Kiemeney,et al.  Genetic susceptibility to prostate cancer: a review , 2004, Familial Cancer.

[23]  C. Kuhl,et al.  Surveillance of "high risk" women with proven or suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial , 2003 .

[24]  F. Graziano,et al.  The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  K. Offit,et al.  Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[27]  Kenneth Offit,et al.  Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. , 2003, Journal of the National Cancer Institute.

[28]  K. Nathanson,et al.  Pheochromocytoma: the expanding genetic differential diagnosis. , 2003, Journal of the National Cancer Institute.

[29]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[30]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Adopted on March American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. R. Lonser,et al.  von Hippel-Lindau disease , 2003, The Lancet.

[33]  R. Hruban,et al.  Fanconi anemia gene mutations in young-onset pancreatic cancer. , 2003, Cancer research.

[34]  P. Radice,et al.  Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. L. Baldwin,et al.  Improved survival in women with BRCA‐associated ovarian carcinoma , 2003, Cancer.

[36]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[37]  P. Pharoah,et al.  Prediction of pathogenic mutations in patients with early-onset breast cancer by family history , 2003, The Lancet.

[38]  J. Varley Germline TP53 mutations and Li‐Fraumeni syndrome , 2003, Human mutation.

[39]  J. Gray,et al.  The genetics and genomics of cancer , 2003, Nature Genetics.

[40]  L. Lipton,et al.  Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. , 2003, The New England journal of medicine.

[41]  Marianne Berwick,et al.  A 20-year perspective on the International Fanconi Anemia Registry (IFAR). , 2003, Blood.

[42]  A. Ziegler,et al.  BRCA2 germline mutations in familial pancreatic carcinoma. , 2003, Journal of the National Cancer Institute.

[43]  R. Hruban,et al.  Familial pancreatic cancer: where are we in 2003? , 2003, Journal of the National Cancer Institute.

[44]  M. Claustres,et al.  First preimplantation genetic diagnosis of hereditary retinoblastoma using informative microsatellite markers. , 2003, Molecular human reproduction.

[45]  J. Varley TP53, hChk2, and the Li-Fraumeni syndrome. , 2003, Methods in molecular biology.

[46]  L. Strong General keynote: hereditary cancer: lessons from Li-Fraumeni syndrome. , 2003, Gynecologic oncology.

[47]  F. Couch,et al.  Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. , 2002, Journal of the National Cancer Institute.

[48]  C. Eng,et al.  The pressure rises: update on the genetics of phaeochromocytoma. , 2002, Human molecular genetics.

[49]  O. Bratt Hereditary prostate cancer: clinical aspects. , 2002, The Journal of urology.

[50]  C. Begg On the use of familial aggregation in population-based case probands for calculating penetrance. , 2002, Journal of the National Cancer Institute.

[51]  T. Beaty,et al.  Evidence for a major gene influencing risk of pancreatic cancer , 2002, Genetic epidemiology.

[52]  G. Parmigiani,et al.  Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families , 2002, Journal of medical genetics.

[53]  Kathleen M Murphy,et al.  Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. , 2002, Cancer research.

[54]  Florence Demenais,et al.  Geographical variation in the penetrance of CDKN2A mutations for melanoma. , 2002, Journal of the National Cancer Institute.

[55]  Hans Joenje,et al.  Biallelic Inactivation of BRCA2 in Fanconi Anemia , 2002, Science.

[56]  C. Eng Role of PTEN, a Lipid Phosphatase Upstream Effector of Protein Kinase B, in Epithelial Thyroid Carcinogenesis , 2002, Annals of the New York Academy of Sciences.

[57]  B. Levin,et al.  A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis , 2002, Gut.

[58]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[59]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[60]  J. Schipper,et al.  Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.

[61]  S. Piantadosi,et al.  Primary chemoprevention of familial adenomatous polyposis with sulindac , 2002 .

[62]  Leonid Kruglyak,et al.  A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. , 2002, American journal of human genetics.

[63]  Sean V Tavtigian,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Douglas F. Easton,et al.  Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.

[65]  R. Peek,et al.  Hereditary diffuse gastric cancer: more answers or more questions? , 2002, Gastroenterology.

[66]  Daniel J Sargent,et al.  Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  J. Church,et al.  Attenuated Familial Adenomatous Polyposis , 2002, Diseases of the colon and rectum.

[68]  S. Rechitsky,et al.  Preimplantation genetic diagnosis for cancer predisposition. , 2002, Reproductive biomedicine online.

[69]  R. Hruban,et al.  Familial pancreatic cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  John P. Bilezikian,et al.  CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 , 2001 .

[71]  T. Sellers,et al.  Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. , 2001, Journal of the National Cancer Institute.

[72]  J. Harbour,et al.  Molecular basis of low-penetrance retinoblastoma. , 2001, Archives of ophthalmology.

[73]  K. Kinzler,et al.  The role of hPMS1 and hPMS2 in predisposing to colorectal cancer. , 2001, Cancer research.

[74]  D. Schaid,et al.  The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. , 2001, American journal of human genetics.

[75]  T. Dryja,et al.  RB1 genetic testing as a clinical service: a follow-up study. , 2001, Medical and pediatric oncology.

[76]  S Wacholder,et al.  Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[77]  J. Klijn,et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[78]  B. Petersen,et al.  Germline E‐cadherin gene mutations , 2001, Cancer.

[79]  G. Petersen,et al.  AGA technical review on hereditary colorectal cancer and genetic testing. , 2001, Gastroenterology.

[80]  C. Caldas,et al.  Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. , 2001, The New England journal of medicine.

[81]  L. McCahill,et al.  The power of genetics to target surgical prevention. , 2001, The New England journal of medicine.

[82]  P. Lynch COX-2 inhibition in clinical cancer prevention. , 2001, Oncology.

[83]  S. Olschwang,et al.  Familial Adenomatous Polyposis: Prevalence of Adenomas in the Ileal Pouch After Restorative Proctocolectomy , 2001, Annals of surgery.

[84]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[85]  O. Olopade,et al.  Male breast cancer in Cowden syndrome patients with germlinePTEN mutations , 2001, Journal of medical genetics.

[86]  W. Linehan,et al.  Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma , 2001, Annals of Internal Medicine.

[87]  J. Fraumeni,et al.  Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[88]  D. Easton,et al.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. , 2001, American journal of human genetics.

[89]  S. Ganesan,et al.  Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. , 2001, Molecular cell.

[90]  K. Heimdal,et al.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.

[91]  M. Choti,et al.  NCCN Practice Guidelines for Colorectal Cancer. , 2000, Oncology.

[92]  T. Powles,et al.  Chemoprevention options for BRCA1 and BRCA2 mutation carriers. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  C. Eng Will the real Cowden syndrome please stand up: revised diagnostic criteria , 2000, Journal of medical genetics.

[94]  B. Weber,et al.  Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. , 2000, American journal of human genetics.

[95]  N. Gruis,et al.  Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16‐Leiden) , 2000, International journal of cancer.

[96]  J. Garber,et al.  Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps. , 2000, JAMA.

[97]  Å. Borg,et al.  High Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation-Positive Melanoma Families , 2000 .

[98]  H. Hampel,et al.  Hereditary colorectal cancer: risk assessment and management , 2000, Clinical genetics.

[99]  P. Chappuis,et al.  Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. , 2000, Seminars in surgical oncology.

[100]  J. Boyd,et al.  Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. , 2000, JAMA.

[101]  L. Aaltonen,et al.  Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. , 2000, Gastroenterology.

[102]  B. Devlin,et al.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.

[103]  S. Gallinger,et al.  Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. , 2000, Cancer research.

[104]  D. Ahlquist,et al.  Care of patients and their families with familial adenomatous polyposis. , 2000, Mayo Clinic proceedings.

[105]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[106]  I. Andrulis,et al.  Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  P. Choyke,et al.  Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. , 1999, The Journal of urology.

[108]  C Eng,et al.  PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. , 1999, Human molecular genetics.

[109]  W. Linehan,et al.  Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. , 1999, The New England journal of medicine.

[110]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[111]  L. Aaltonen,et al.  Cancer risk in mutation carriers of DNA‐mismatch‐repair genes , 1999, International journal of cancer.

[112]  S. Markowitz,et al.  E‐cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer , 1999, Human mutation.

[113]  H. Olsson Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[114]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[115]  D. Birnbaum,et al.  BRCA1 and medullary breast cancer. , 1998, JAMA.

[116]  D. Evans,et al.  Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndrome , 1998, Oncogene.

[117]  A. Zwinderman,et al.  Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. , 1998, The New England journal of medicine.

[118]  B. Ponder,et al.  Oral Contraceptives and the Risk of Hereditary Ovarian Cancer , 1998 .

[119]  S N Thibodeau,et al.  Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. , 1998, Cancer research.

[120]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[121]  D. Albert,et al.  Trilateral retinoblastoma: insights into histogenesis and management. , 1998, Survey of ophthalmology.

[122]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[123]  C. Boland,et al.  A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. , 1997, Journal of the National Cancer Institute.

[124]  H. Ostrer,et al.  Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC , 1997, Nature Genetics.

[125]  B. Gallie Predictive testing for retinoblastoma comes of age. , 1997, American journal of human genetics.

[126]  B. Lorenz,et al.  Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. , 1997, American journal of human genetics.

[127]  B. Ponder,et al.  Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. , 1997, Human molecular genetics.

[128]  J. Eyfjörd,et al.  Study of a single BRCA2 mutation with high carrier frequency in a small population. , 1997, American journal of human genetics.

[129]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.

[130]  Y Wang,et al.  Positional cloning of the gene for multiple endocrine neoplasia-type 1. , 1997, Science.

[131]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[132]  E. Thomson,et al.  Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2 , 1997 .

[133]  K Offit,et al.  Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. , 1997, JAMA.

[134]  E. Thomson,et al.  Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: I. Hereditary Nonpolyposis Colon Cancer , 1997 .

[135]  E. Thomson,et al.  Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. , 1997, JAMA.

[136]  A S Whittemore,et al.  Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. , 1997, American journal of human genetics.

[137]  G. Coetzee,et al.  Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. , 1997, Journal of the National Cancer Institute.

[138]  G. Chenevix-Trench,et al.  Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident. , 1997, American journal of human genetics.

[139]  J. Fraumeni,et al.  Hereditary retinoblastoma, lipoma, and second primary cancers. , 1997, Journal of the National Cancer Institute.

[140]  T. Smyrk,et al.  An update of HNPCC (Lynch syndrome). , 1997, Cancer genetics and cytogenetics.

[141]  D. Evans,et al.  Li-Fraumeni syndrome--a molecular and clinical review. , 1997, British Journal of Cancer.

[142]  D. Evans,et al.  PATIENTS AND METHODS , 1981 .

[143]  D A Meyers,et al.  Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search , 1996, Science.

[144]  C Eng,et al.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. , 1996, JAMA.

[145]  J. Mohler,et al.  Association of prostate cancer with vitamin D receptor gene polymorphism. , 1996, Cancer research.

[146]  A. Detsky,et al.  Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. , 1996, American journal of human genetics.

[147]  M. Rodriguez-Bigas Prophylactic colectomy for gene carriers in hereditary nonpolyposis colorectal cancer: Has the time come? , 1996, Cancer.

[148]  R. Myers,et al.  Human Homolog of patched, a Candidate Gene for the Basal Cell Nevus Syndrome , 1996, Science.

[149]  K. Kinzler,et al.  Analysis of mismatch repair genes in hereditary non–polyposis colorectal cancer patients , 1996, Nature Medicine.

[150]  J. Norton,et al.  Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. , 1996, Journal of pediatric surgery.

[151]  N. Hayward,et al.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.

[152]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[153]  A M Goldstein,et al.  Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. , 1995, The New England journal of medicine.

[154]  F. Nagengast,et al.  Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome) , 1995, The Lancet.

[155]  P. Sistonen,et al.  Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. , 1995, Gastroenterology.

[156]  B. Ponder,et al.  Prophylactic oophorectomy in inherited breast/ovarian cancer families. , 1995, Journal of the National Cancer Institute. Monographs.

[157]  M. Skolnick,et al.  Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). , 1994, Cancer research.

[158]  T. G. Parks,et al.  Familial adenomatous polyposis , 1994, The British journal of surgery.

[159]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[160]  A. Cats,et al.  Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols. , 1994, Gut.

[161]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[162]  S. O. Krolls,et al.  Malignant Potential of the Odontogenic Keratocyst , 1994, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[163]  D. Ward,et al.  Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer , 1994, Nature.

[164]  R. Thakker,et al.  Multiple endocrine neoplasia type 1 (MEN1). , 1994, European journal of cancer.

[165]  Robin J. Leach,et al.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer , 1993, Cell.

[166]  N. Copeland,et al.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer , 1993, Cell.

[167]  G. Thomas,et al.  Alleles of the APC gene: An attenuated form of familial polyposis , 1993, Cell.

[168]  C. Eng,et al.  Mortality From Second Tumors Among Long-Term Survivors of Retinoblastoma , 1993 .

[169]  D. Evans,et al.  Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. , 1993, Journal of medical genetics.

[170]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[171]  K. Kinzler,et al.  Clues to the pathogenesis of familial colorectal cancer. , 1993, Science.

[172]  A. Goodman,et al.  The benefit and cost of prostate cancer early detection , 1993, CA: a cancer journal for clinicians.

[173]  W. Clark,et al.  Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. , 1993, American journal of human genetics.

[174]  H. Lynch,et al.  Extracolonic cancer in hereditary nonpolyposis colorectal cancer , 1993 .

[175]  M. Skolnick,et al.  Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. , 1992, Science.

[176]  M. Skolnick,et al.  A screening study of prostate cancer in high risk families. , 1992, Journal of Urology.

[177]  R. Weichselbaum,et al.  Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. , 1992, The New England journal of medicine.

[178]  S. S. Kroll,et al.  Primary breast cancer after prophylactic mastectomy. , 1991, American journal of clinical oncology.

[179]  S. Altschul,et al.  Identification of FAP locus genes from chromosome 5q21. , 1991, Science.

[180]  H T Lynch,et al.  Hereditary colorectal cancer. , 1991, Seminars in oncology.

[181]  H. Vasen,et al.  Screening for the multiple endocrine neoplasia syndrome type I. A study of 11 kindreds in The Netherlands. , 1989, Archives of internal medicine.

[182]  P. Green,et al.  Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. , 1989, The New England journal of medicine.

[183]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[184]  Robert J. Gorlin,et al.  Nevoid Basal‐Cell Carcinoma Syndrome , 1987, Medicine.

[185]  Stephen H. Friend,et al.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma , 1986, Nature.

[186]  A. Hover,et al.  Cowden disease. A hereditary polyposis syndrome diagnosable by mucocutaneous inspection. , 1986, Journal of clinical gastroenterology.

[187]  R. Elston,et al.  Segregation analysis of hereditary nonpolyposis colorectal cancer , 1986, Genetic epidemiology.

[188]  W. Clark,et al.  Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. , 1985, The New England journal of medicine.

[189]  H. Lynch,et al.  Surveillance and Management of Patients at High Genetic Risk for Ovarian Carcinoma , 1982, Obstetrics and gynecology.

[190]  W. Clark,et al.  Precursor Lesions in Familial Melanoma: A New Genetic Preneoplastic Syndrome , 1978 .

[191]  L. Strong Genetic and environmental interactions , 1977, Cancer.

[192]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[193]  J. Fraumeni,et al.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.

[194]  R. Gorlin,et al.  Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. , 1960, The New England journal of medicine.